Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia
Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia
复制标题
DOI：
10.1016/j.leukres.2009.01.001
复制
发表时间：
2009-08-01
影响因子：
2.7
通讯作者：
McKenzie, J. L.
中科院分区：
文献类型：
--
作者：
Hock, B. D.;Fernyhough, L. J.;McKenzie, J. L.
可溶性CD83(SCD83)是一种有效的免疫抑制剂，在一些慢性淋巴细胞白血病(CLL)患者中循环水平升高。我们报告血浆sCD83水平升高的慢性淋巴细胞性白血病患者无治疗生存期显著缩短(P=0.038)。CD83mAb与IL-4联合培养可显著增加CD83的释放(23~117倍，P=0.013)，而单用CD83mAb连接正常供者外周血可显著增加sCD83的释放(P=0.003)。RT-PCR分析检测到2/3的CLL标本中存在sCD83的转录本。这些结果提示，sCD83的释放可能在CLL的进展中起到调节作用。(C)2009爱思唯尔有限公司。保留所有权利。
Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb+IL-4 significantly increases sCD83 release (23-117-fold, P=0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P=0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression. (C) 2009 Elsevier Ltd. All rights reserved.